Is VRAX or VTGN more undervalued in 2026?

CirclFi compares Virax Biolabs Group Limited (VRAX) and VistaGen Therapeutics, Inc. (VTGN) using 13 institutional-grade valuation models. VRAX has a Quality of Company score of 1.6/10 while VTGN scores 6.0/10.

Which is a better buy — VRAX or VTGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VRAX and VTGN valuations compare?

VRAX at $0.21 and VTGN at $0.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VRAX vs VTGN Valuation Comparison 2026 — Intrinsic Value Analysis

VRAX

Biotechnology

Virax Biolabs Group Limited

Quality

1.6

out of 10

Value Trap

SAFE

Price

$0.21

Last close

Models

8/13

Active

VTGN

Biotechnology

VistaGen Therapeutics, Inc.

Quality

6.0

out of 10

Value Trap

LOW

Price

$0.63

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	VRAX Fair Value	VRAX Upside	VTGN Fair Value	VTGN Upside
Bayesian DCF	Intrinsic	$0.06	-73.5%	$0.81	+27.9%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.41	+85.4%	$2.62	+313.1%
PWERM	Option-Based	$0.28	+125.8%	$0.92	+44.5%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VRAX vs VTGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VRAX vs VTGN — Which Stock Is More Undervalued?

VTGN scores higher with a 6.0/10 quality rating vs VRAX's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Virax Biolabs Group Limited (VRAX) and VistaGen Therapeutics, Inc. (VTGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VRAX currently trades at $0.21 with a QOC of 1.6/10, while VTGN trades at $0.63 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).